No profile data available.
West Pharmaceutical Services, Inc. (WST) is a healthcare company in the additional medication administration equipment industry, based in Exton, United States, with about 10,800 full-time employees.
It reported revenue of $3.07 billion for fiscal year 2025, up 6.3% from fiscal year 2024, and net income of $493.70 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $872.30 million, up 13.8% from a year before. Its largest business segment, Proprietary Products, brought in 81% of segment revenue in fiscal year 2025; United States was the largest region with 43%. Its market capitalization was $25.76 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.
West Pharmaceutical Services reported $3.07 billion in revenue for fiscal year 2025, up 6.3% from $2.89 billion in fiscal year 2024. In Q2 2026 revenue was $872.30 million.
Proprietary Products, with $2.49 billion or 81% of segment revenue in fiscal year 2025. Next: West Vantage (19%).
United States: 43% of revenue by region in fiscal year 2025, followed by Other European Countries (15%).
$25.76 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional medication administration equipment) include Stevanato Group S.p.A. (STVN), Embecta Corp. (EMBC), Retractable Technologies, Inc. (RVP), Biora Therapeutics, Inc. (BIOR).